These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24381657)

  • 1. Taxanes: vesicants, irritants, or just irritating?
    Barbee MS; Owonikoko TK; Harvey RD
    Ther Adv Med Oncol; 2014 Jan; 6(1):16-20. PubMed ID: 24381657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Oncology Nursing Society extravasation guidelines.
    Wengström Y; Margulies A;
    Eur J Oncol Nurs; 2008 Sep; 12(4):357-61. PubMed ID: 18765210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing and managing vesicant chemotherapy extravasations.
    Schulmeister L
    J Support Oncol; 2010; 8(5):212-5. PubMed ID: 21086879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for Management of Noncytotoxic Vesicant Extravasations.
    Ong J; Van Gerpen R
    J Infus Nurs; 2020; 43(6):319-343. PubMed ID: 33141794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy Extravasation: Establishing a National Benchmark for Incidence Among Cancer Centers.
    Jackson-Rose J; Del Monte J; Groman A; Dial LS; Atwell L; Graham J; O'Neil Semler R; O'Sullivan M; Truini-Pittman L; Cunningham TA; Roman-Fischetti L; Costantinou E; Rimkus C; Banavage AJ; Dietz B; Colussi CJ; Catania K; Wasko M; Schreffler KA; West C; Siefert ML; Rice RD
    Clin J Oncol Nurs; 2017 Aug; 21(4):438-445. PubMed ID: 28738039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Evidence-Based List of Non-Antineoplastic Vesicants: 2024 Update.
    Gorski LA; Ong J; Van Gerpen R; Nickel B; Kokotis K; Hadaway L
    J Infus Nurs; 2024 Sep-Oct 01; 47(5):290-323. PubMed ID: 39250767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vesicant extravasation: myths and realities.
    Boyle DM; Engelking C
    Oncol Nurs Forum; 1995; 22(1):57-67. PubMed ID: 7708525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extravasation of Noncytotoxic Agents: Skin Injury and Risk Classification.
    Shibata Y; Taogoshi T; Matsuo H
    Biol Pharm Bull; 2023; 46(6):746-755. PubMed ID: 37258139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing vesicant extravasations.
    Schulmeister L
    Oncologist; 2008 Mar; 13(3):284-8. PubMed ID: 18378538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicant extravasation part II: Evidence-based management and continuing controversies.
    Wickham R; Engelking C; Sauerland C; Corbi D
    Oncol Nurs Forum; 2006 Nov; 33(6):1143-50. PubMed ID: 17149397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infiltration and Extravasation Risk with Midline Catheters: A Narrative Literature Review.
    Hadaway L; Gorski LA
    J Infus Nurs; 2024 Sep-Oct 01; 47(5):324-346. PubMed ID: 39250768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extravasation management.
    Schulmeister L
    Semin Oncol Nurs; 2007 Aug; 23(3):184-90. PubMed ID: 17693345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center.
    Ehmke N
    Clin J Oncol Nurs; 2021 Dec; 25(6):680-686. PubMed ID: 34800094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and treatment of chemotherapy extravasation injuries.
    Kassner E
    J Pediatr Oncol Nurs; 2000 Jul; 17(3):135-48. PubMed ID: 10944862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidotes to vesicant chemotherapy extravasations.
    Dorr RT
    Blood Rev; 1990 Mar; 4(1):41-60. PubMed ID: 2182147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an Evidence-Based List of Noncytotoxic Vesicant Medications and Solutions.
    Gorski LA; Stranz M; Cook LS; Joseph JM; Kokotis K; Sabatino-Holmes P; Van Gosen L;
    J Infus Nurs; 2017; 40(1):26-40. PubMed ID: 28030480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk.
    Sauerland C; Engelking C; Wickham R; Corbi D
    Oncol Nurs Forum; 2006 Nov; 33(6):1134-41. PubMed ID: 17149396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GEDEFO-SEFH management of antineoplastic extravasations survey results.
    Jiménez-Pulido I; Albert-Marí MA; Conde-Estévez D; San José-Ruiz B; Gil-Lemus MÁ; Cercós-LLetí AC; Esteban-Mensua MJ; Díaz-Carrasco MS
    J Oncol Pharm Pract; 2024 Jan; 30(1):67-77. PubMed ID: 37032471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of anticancer agent extravasation: A single institutional guideline.
    Kimmel J; Fleming P; Cuellar S; Anderson J; Haaf CM
    J Oncol Pharm Pract; 2018 Mar; 24(2):129-138. PubMed ID: 29284352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy extravasation from implanted ports.
    Schulmeister L; Camp-Sorrell D
    Oncol Nurs Forum; 2000 Apr; 27(3):531-8; quiz 539-40. PubMed ID: 10785905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.